BeiGene Forms $330 Million JV for Guangzhou Biologics Manufacturing Facility

BeiGene of Beijing is forming a $330 million JV, BeiGene Biologics, that will build a Guangzhou biologic drug manufacturing facility with Guangzhou GET Technology Development. BeiGene will contribute $30 million to the JV, Guangzhou GET will invest $150 million in a combination of direct equity investment and a convertible shareholder loan, and the JV will raise another $150 million in commercial loans. Some of the funds may be used to support China biologic drug development. Construction of the new facility will begin this year. More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //